CEO Mark Lappe was paid $2,892,473 in fiscal year 2025, ↓ down 38.5% from fiscal year 2024 (SEC filing 0002007919-26-000014 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$2,892,473 ↓ Mark Lappe total, FY2025 | — CEO pay percentile vs peers | — CEO-to-median pay ratio | — Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
INBX's next annual pay disclosure, estimated April 23, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mark Lappe | $695,250 | $1,700,000 | $0 | $0 | $479,723 | $0 | $17,500 | $2,892,473 |
| Chief Executive Officer and Chairman of the Board of Directors | ||||||||
| David Matly | 589,170 | 0 | 0 | 524,285 | 304,985 | 0 | 17,500 | 1,435,940 |
| President | ||||||||
| Kelly Deck | 493,485 | 0 | 0 | 157,286 | 255,425 | 0 | 17,500 | 923,696 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Mark Lappe | $2,892,473 | $4,703,058 | — | ↓ −1,810,585 |
| David Matly | 1,435,940 | — | — | — |
| Kelly Deck | 923,696 | 4,275,323 | — | ↓ −3,351,627 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Inhibrx Biosciences, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper INBX reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Inhibrx Biosciences, Inc. Peer Teardown Report
$2,892,473 Mark Lappe total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 14, 2026 · Source: 0002007919-26-000014 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for INBX
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order INBX
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
Each company listed discloses INBX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named INBX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Get the Inhibrx Biosciences, Inc. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Douglas G. Forsyth | Independent Director | $202,685 |
| Jon Faiz Kayyem, Ph.D | Independent Director | $192,185 |
| Kimberly Manhard | Independent Director | $183,685 |
| Kristiina Vuori, M.D., Ph.D | Independent Director | $186,185 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| David Matly | President | 2026-04-24 | A | 50,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Kristiina Vuori MD | Director | 2026-06-03 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Douglas G. Forsyth | Director | 2026-06-03 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kristiina Vuori MD | Director | 2026-06-03 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly Manhard | Director | 2026-06-03 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jon Faiz Kayyem | Director | 2026-06-03 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jon Faiz Kayyem | Director | 2026-06-03 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly Manhard | Director | 2026-06-03 | A | 10,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Douglas G. Forsyth | Director | 2026-06-03 | A | 15,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kimberly Manhard | Director | 2026-09-08 | D | 500 | 115 | 57,570 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-08 | A | 1,100 | 107 | 117,836 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-08 | A | 5,895 | 99 | 585,343 | Common | Form 4 ↗ |
| Douglas G. Forsyth | Director | 2026-09-08 | A | 2,500 | 115 | 286,617 | Common | Form 4 ↗ |
| Jon Faiz Kayyem | Director | 2026-09-08 | A | 5,000 | 114 | 567,580 | Common, indirect | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-08 | A | 9,681 | 112 | 1,087,001 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-08 | A | 500 | 108 | 54,118 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-08 | A | 6,605 | 101 | 664,719 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-08 | A | 1,219 | 112 | 136,382 | Common | Form 4 ↗ |
| Kimberly Manhard | Director | 2026-09-09 | D | 500 | 116 | 57,898 | Common | Form 4 ↗ |
| Kimberly Manhard | Director | 2026-09-11 | D | 500 | 112 | 55,888 | Common | Form 4 ↗ |
| Kimberly Manhard | Director | 2026-09-14 | D | 500 | 110 | 55,130 | Common | Form 4 ↗ |
| Kimberly Manhard | Director | 2026-09-15 | D | 500 | 105 | 52,525 | Common | Form 4 ↗ |
| Jon Faiz Kayyem | Director | 2026-09-16 | A | 5,000 | 100 | 500,000 | Common, indirect | Form 4 ↗ |
| Jon Faiz Kayyem | Director | 2026-09-23 | A | 5,000 | 100 | 500,000 | Common, indirect | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-25 | A | 3,324 | 99 | 328,630 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-25 | A | 2,176 | 100 | 216,727 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-28 | A | 1,500 | 99 | 148,320 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-09-28 | A | 3,000 | 102 | 305,106 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-10-14 | A | 100 | 86 | 8,576 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-10-14 | A | 2,451 | 85 | 208,333 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-10-14 | A | 2,449 | 84 | 205,889 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-10-14 | A | 100 | 86 | 8,576 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-10-14 | A | 2,470 | 85 | 209,948 | Common | Form 4 ↗ |
| Mark Lappe | Director | 2026-10-14 | A | 2,470 | 84 | 207,655 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Matly | OPTION | — | — | — | — | — | $524,285 |
| Kelly Deck | OPTION | — | — | — | — | — | 157,286 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Matly | $0 | $0 | $524,285 | 0.0% |
| Kelly Deck | 0 | 0 | 157,286 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| David Matly | Option | 50,000 | 14.05 | — |
| Mark Lappe | Option | 181,250 | 15.86 | — |
| David Matly | Option | 105,729 | 15.86 | — |
| Kelly Deck | Option | 105,729 | 15.86 | — |
| Kelly Deck | Option | 15,000 | 14.05 | — |
The Company's compensation philosophy is designed to reward executives for overall Company performance in a given year and to align the interests of executive officers with stockholders through equity grants that provide a strong link to long-term performance and promote retention.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-03 | — | — | — | — | — |
| 2025 | 2025-05-28 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-03 | —a |
| 2025 | 2025-05-28 | —b |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Douglas G. ForsythIndependent · Audit (Chair) · Compensation · Nominating and Corporate Governance (Chair) | $63,000 | — | $139,685 | — | — | $202,685 |
| Jon Faiz Kayyem, Ph.DIndependent · Audit · Compensation (Chair) | 52,500 | 0 | 139,685 | 0 | 0 | 192,185 |
| Kristiina Vuori, M.D., Ph.DIndependent · Audit · Nominating and Corporate Governance | 46,500 | — | 139,685 | — | — | 186,185 |
| Kimberly ManhardIndependent · Compensation · Nominating and Corporate Governance | 44,000 | — | 139,685 | — | — | 183,685 |
| Mark P. LappeEmployee director · Board Chair | — | — | — | — | — | 0 |
| Annual cash retainer | $35,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $206,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $206,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Inhibrx Biosciences, Inc. | 2025 | Mark Lappe | $695,250 | $0 | $0 | $479,723 | $2,892,473 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mark Lappe | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “SUMMARY COMPENSATION TABLE” · page 16. As printed: 2,892,473. Filing ↗machine: span 234894–234903 |
| 2 | Section 01, David Matly | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “SUMMARY COMPENSATION TABLE” · page 16. As printed: 1,435,940. Filing ↗machine: span 252124–252133 |
| 3 | Section 01, Kelly Deck | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “SUMMARY COMPENSATION TABLE” · page 16. As printed: 923,696. Filing ↗machine: span 243449–243456 |
| 4 | Section 03, David Matly OPTION | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t15 · r6 · c13 · span 250289–250296 |
| 5 | Section 03, Kelly Deck OPTION | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t15 · r4 · c13 · span 241614–241621 |
| 6 | Section 07, pay ratio | 10-K | 2026-03-19 | 0002007919-26-000006 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 7 | Section 08, Douglas G. Forsyth | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 202,685. Filing ↗machine: span 195537–195725 |
| 8 | Section 08, Jon Faiz Kayyem, Ph.D | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 192,185. Filing ↗machine: span 198365–198553 |
| 9 | Section 08, Kristiina Vuori, M.D., Ph.D | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 186,185. Filing ↗machine: span 203965–204153 |
| 10 | Section 08, Kimberly Manhard | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 183,685. Filing ↗machine: span 201159–201347 |
| 11 | Section 08, Mark P. Lappe | DEF 14A | 2026-04-23 | 0002007919-26-000014 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 12 | Section 02, David Matly 2026-04-24 | Form 4 | 2026-04-27 | 0002062665-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 13 | Section 02, Kristiina Vuori MD 2026-06-03 | Form 4 | 2026-09-18 | 0001612627-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 14 | Section 02, Douglas G. Forsyth 2026-06-03 | Form 4 | 2026-09-18 | 0001240801-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 15 | Section 02, Kristiina Vuori MD 2026-06-03 | Form 4 | 2026-06-04 | 0001612627-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Kimberly Manhard 2026-06-03 | Form 4 | 2026-06-04 | 0001202094-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Jon Faiz Kayyem 2026-06-03 | Form 4 | 2026-06-04 | 0001366268-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Jon Faiz Kayyem 2026-06-03 | Form 4 | 2026-09-18 | 0001366268-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Kimberly Manhard 2026-06-03 | Form 4 | 2026-09-18 | 0001202094-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Douglas G. Forsyth 2026-06-03 | Form 4 | 2026-06-04 | 0001240801-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Kimberly Manhard 2026-09-08 | Form 4 | 2026-09-10 | 0001202094-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Mark Lappe 2026-09-08 | Form 4 | 2026-09-08 | 0001366074-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Mark Lappe 2026-09-08 | Form 4 | 2026-09-08 | 0001366074-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Douglas G. Forsyth 2026-09-08 | Form 4 | 2026-09-08 | 0001240801-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Jon Faiz Kayyem 2026-09-08 | Form 4 | 2026-09-08 | 0001366268-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Mark Lappe 2026-09-08 | Form 4 | 2026-09-08 | 0001366074-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Mark Lappe 2026-09-08 | Form 4 | 2026-09-08 | 0001366074-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Mark Lappe 2026-09-08 | Form 4 | 2026-09-08 | 0001366074-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Mark Lappe 2026-09-08 | Form 4 | 2026-09-08 | 0001366074-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Kimberly Manhard 2026-09-09 | Form 4 | 2026-09-10 | 0001202094-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Kimberly Manhard 2026-09-11 | Form 4 | 2026-09-15 | 0001202094-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Kimberly Manhard 2026-09-14 | Form 4 | 2026-09-15 | 0001202094-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Kimberly Manhard 2026-09-15 | Form 4 | 2026-09-15 | 0001202094-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Jon Faiz Kayyem 2026-09-16 | Form 4 | 2026-09-17 | 0001366268-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Jon Faiz Kayyem 2026-09-23 | Form 4 | 2026-09-23 | 0001366268-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Mark Lappe 2026-09-25 | Form 4 | 2026-09-28 | 0001366074-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Mark Lappe 2026-09-25 | Form 4 | 2026-09-28 | 0001366074-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Mark Lappe 2026-09-28 | Form 4 | 2026-09-28 | 0001366074-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Mark Lappe 2026-09-28 | Form 4 | 2026-09-28 | 0001366074-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Mark Lappe 2026-10-14 | Form 4 | 2026-10-14 | 0001366074-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Mark Lappe 2026-10-14 | Form 4 | 2026-10-14 | 0001366074-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Mark Lappe 2026-10-14 | Form 4 | 2026-10-14 | 0001366074-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Mark Lappe 2026-10-14 | Form 4 | 2026-10-14 | 0001366074-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Mark Lappe 2026-10-14 | Form 4 | 2026-10-14 | 0001366074-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Mark Lappe 2026-10-14 | Form 4 | 2026-10-14 | 0001366074-26-000006 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 06, 2026 vote | Form 8-K | 2026-06-03 | 0002007919-26-000030 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 47 | Section 06, 2025 vote | Form 8-K | 2025-05-28 | 0002007919-25-000063 | Item 5.07 · say-on-pay result. As reported: —. Filing ↗ |
| 48 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 49 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 50 | Section 09b board cost (computed) | Computed | — | — | Cash 206,000 + equity 0 + all other 0 = 206,000, summed across the director compensation table rows.machine: formula: Σ = 206,000 |
| 51 | Inhibrx Biosciences, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0002007919-26-000014 | CEO total compensation as printed in Inhibrx Biosciences, Inc.'s own proxy. As printed: 2,892,473. Filing ↗machine: span 234894–234903 |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Inhibrx Biosciences, Inc. Executive Compensation Report
$1,500